Neurogene Inc. Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value
Neurogene Inc. (NGNE) had Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value of $0 as of 2015-09-30, per its 10-Q filed 2015-11-10.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue · last filed 2015-11-10
- 2015-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $0.00.
- 2015-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $0.00.
- 2014-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $0.00.
- 2013-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $0.00.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value |
|---|---|
| 2015-09-30 | $0.00 10-Q · filed 2015-11-10 |
| 2015-06-30 | $0.00 10-Q · filed 2015-08-06 |
| 2014-03-31 | $0.00 10-Q · filed 2015-05-12 |
| 2013-12-31 | $0.00 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |